Alpha lipoic acid (ALA) shows real promise for reducing neuropathy symptoms like burning, tingling, and numbness, particularly in people with diabetes. The strongest evidence supports intravenous use, while results for oral supplements are more mixed. A daily oral dose of 600 mg for at least 12 weeks is the most commonly studied regimen, and many people report meaningful relief within that window, though the improvements tend to be modest rather than dramatic.
How ALA Works on Damaged Nerves
ALA is a compound your body naturally produces in small amounts. It plays a role in energy production inside cells and acts as a powerful antioxidant. For neuropathy specifically, it works through several pathways at once, which is part of what makes it appealing as a supplement.
First, it directly neutralizes the harmful molecules (free radicals) that accumulate around nerve fibers, especially when blood sugar has been elevated over time. But it also recycles other antioxidants your body relies on, including vitamin C and glutathione, extending their protective effects. It chelates excess iron and copper, which can otherwise fuel oxidative damage. And it reduces inflammation in neural tissue by dialing down pro-inflammatory signaling molecules while boosting anti-inflammatory ones.
Beyond antioxidant activity, ALA improves blood flow to peripheral nerves. It enhances the production of nitric oxide, a molecule that relaxes blood vessels and increases circulation. One randomized trial found that 300 mg per day improved blood vessel dilation by 44% in just four weeks. For nerves starved of oxygen and nutrients due to poor microcirculation, this matters. Better blood flow means better nerve function, and animal studies have confirmed that ALA improves both motor and sensory nerve conduction velocity in diabetic models.
What the Clinical Evidence Actually Shows
The clinical picture for ALA and neuropathy is encouraging but not overwhelming. Several trials have demonstrated that ALA reduces symptom scores for pain, burning, and tingling compared to placebo. Intravenous ALA, given in clinical settings, has shown the most consistent benefits, including improvements in endothelial function in patients with impaired glucose metabolism.
Oral supplementation tells a more nuanced story. A Cochrane review, the gold standard for evaluating medical evidence, found that after six months of oral ALA, the average improvement in neuropathy symptom scores compared to placebo was just 0.16 points. That difference didn’t reach the threshold considered clinically meaningful (0.97 points). The certainty of this evidence was rated moderate, meaning the true effect could be somewhat different from what this single large study captured.
A 12-week study of 30 people with diabetic neuropathy taking 600 mg daily did show improvements in pain, burning, tingling, and numbness, with symptoms scored monthly throughout the trial. So shorter-term relief appears real for some people, even if longer-term data is less convincing. The Mayo Clinic’s current summary puts it plainly: small studies suggest benefit, but results are mixed, and larger studies are still needed.
How It Compares to Standard Medications
Most people with neuropathy are prescribed medications like gabapentin or pregabalin, which work by dampening pain signals in the nervous system. ALA works through a completely different mechanism, targeting the underlying nerve damage rather than just masking symptoms. This makes the two approaches potentially complementary rather than competitive.
One study compared gabapentin alone to gabapentin combined with 600 mg of ALA daily over three months. Both groups saw significant improvements in nerve conduction velocity. But the group taking ALA alongside gabapentin also experienced better blood sugar control, with a significant drop in HbA1c (a measure of average blood sugar over three months). The gabapentin-only group saw no change in blood sugar. This dual benefit is noteworthy because better blood sugar control itself slows the progression of neuropathy.
No large head-to-head trials have directly pitted ALA against gabapentin or pregabalin for pain relief alone, so it’s not possible to say one is definitively better than the other. What the available data suggests is that adding ALA to an existing medication regimen may provide additional nerve function benefits beyond what the medication achieves on its own.
Beyond Diabetic Neuropathy
Most research on ALA and neuropathy focuses on diabetes, but a pilot study in breast cancer patients offers a glimpse at its potential for chemotherapy-induced nerve damage. Twenty women who developed peripheral neuropathy during treatment with a common chemotherapy drug started taking 300 mg of ALA daily in liquid form. Of those 20 patients, 16 (80%) experienced some degree of relief. The median time to noticing improvement was 21 days, with some responding in as little as one week and others taking up to 12 weeks.
These are very preliminary findings from a small, uncontrolled study, so they should be interpreted cautiously. But they suggest ALA’s nerve-protective effects aren’t limited to damage caused by high blood sugar. The underlying mechanism, reducing oxidative stress on nerve fibers, is relevant regardless of what’s causing the damage in the first place.
Dosage and What to Expect
Clinical doses for neuropathy range from 200 to 2,400 mg per day, but 600 mg daily is the most commonly studied and widely recommended dose. There is no established consensus on a single best dose. Some trials have tested 1,200 mg and 1,800 mg per day without clear evidence that higher amounts work significantly better than 600 mg, while side effects tend to increase at higher doses.
Most studies showing benefit run for at least 12 weeks, so patience matters. This is not a supplement that works overnight. If you’re going to try it, committing to a three-month trial at 600 mg daily gives you the best chance of matching the conditions under which positive results have been observed.
ALA supplements come in two forms: a racemic mixture (labeled as “alpha lipoic acid”) containing both R and S isomers, and pure R-alpha lipoic acid. The R form is what your body naturally produces and uses as a cofactor in mitochondrial energy reactions. It’s also the form specifically studied in the chemotherapy-induced neuropathy trial. R-ALA supplements tend to cost more, and while there are theoretical reasons to prefer the R form based on its biological activity, most of the large neuropathy trials used the standard racemic mixture.
Safety and Blood Sugar Concerns
ALA is generally well tolerated. The most common side effects are gastrointestinal: nausea, heartburn, and stomach discomfort, which typically resolve if you take it with food or lower the dose.
The more important concern, particularly for people with diabetes, is its effect on blood sugar. ALA can lower blood glucose, which is beneficial in moderation but potentially dangerous if you’re already taking insulin or other glucose-lowering medications. Health Canada has specifically flagged the risk of hypoglycemia, noting that ALA may trigger a condition called insulin autoimmune syndrome in people with a specific genetic variation. Symptoms of low blood sugar to watch for include sweating, paleness, chills, headache, dizziness, and confusion.
If you take diabetes medications, monitoring your blood sugar more frequently when starting ALA is a practical step. The blood sugar-lowering effect isn’t always a downside. In the study combining ALA with gabapentin, the improvement in HbA1c was considered a benefit. But it does mean your medication doses may need adjustment, which is a conversation worth having with whoever manages your diabetes care.